Company Filing History:
Years Active: 1996
Title: The Innovations of Philip A. Gordon
Introduction
Philip A. Gordon is an accomplished inventor based in Edmonton, Canada. With a focus on advancements in medical technology, he has made significant contributions to the field, particularly through his work on phospholipid coated particles. His innovative approach aids in the detection and isolation of antiphospholipid antibodies, which can have important implications for medical diagnostics.
Latest Patents
Gordon holds a patent titled "Methods for preparing phospholipid coated particles and for eliciting." This invention provides phospholipid coated particles that are capable of specifically binding antiphospholipid antibodies. Additionally, Gordon’s patent outlines methods for preparing these particles, determining antiphospholipid antibodies in serum or plasma, and isolating these antibodies from fluids. This work has the potential to advance the understanding and treatment of conditions associated with antiphospholipid antibodies.
Career Highlights
Philip A. Gordon is affiliated with the University Hospitals Board, where he contributes his expertise in medical research and innovation. His role at this institution allows him to collaborate with other experts in the field, further enhancing the impact of his inventions on healthcare.
Collaborations
Throughout his career, Gordon has worked alongside notable individuals such as Michael William Stewart and Wai Sum Etches. These collaborations have fostered an environment of innovation, enabling the development of methods that improve diagnostics and patient care.
Conclusion
With his patent and collaborative efforts, Philip A. Gordon exemplifies the spirit of innovation within the medical technology sector. His work not only addresses critical healthcare challenges but also contributes to the body of knowledge on antiphospholipid antibodies, paving the way for further advancements in the field. As he continues to develop his ideas, the potential for future innovations remains promising.